AnaptysBio (NASDAQ:ANAB) Announces Quarterly Earnings Results

AnaptysBio (NASDAQ:ANAB) posted its earnings results on Thursday. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.89, Zacks reports. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB traded down $0.60 during mid-day trading on Thursday, hitting $16.40. The stock had a trading volume of 487,807 shares, compared to its average volume of 1,092,114. The company has a market cap of $499.05 million and a PE ratio of -2.70. AnaptysBio has a 12-month low of $12.21 and a 12-month high of $41.31. The company’s 50 day moving average is $15.94 and its 200-day moving average is $24.89.

Insider Activity at AnaptysBio

In other news, Director Ecor1 Capital, Llc purchased 6,646 shares of AnaptysBio stock in a transaction that occurred on Thursday, January 2nd. The stock was acquired at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the transaction, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 33.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Guggenheim decreased their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Wolfe Research assumed coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 price objective for the company. Wells Fargo & Company increased their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. HC Wainwright reiterated a “neutral” rating and issued a $19.00 price objective on shares of AnaptysBio in a report on Tuesday, February 4th. Finally, UBS Group increased their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and an average target price of $34.11.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.